Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis

Xiaowen Zhang1†, Fei Shao1,2†, Lin Zhu1, Yuyang Ze1, Dalong Zhu1* and Yan Bi1*

Abstract

Background: Efficacy trials showed that glucagon-like peptide–1 receptor (GLP1R) agonists reduced metabolic risk factors in addition to glucose lowering, but the cardiovascular and microvascular efficacy of this drug class remains to be determined. We aimed to evaluate the overall cardiovascular and microvascular efficacy of GLP1R agonists by performing a meta-analysis with trial sequential analysis.

Methods: Randomized controlled, cardiovascular outcomes trials including at least 2000 patient-years’ follow-up and 100 composite cardiovascular events were included. Trial sequential analysis (TSA) was performed and the quality of evidence was graded.

Results: Thirty-three thousand four hundred fifty-seven patients and 4105 cardiovascular events from 4 large trials were included. GLP1R agonists were associated with a statistically significant reduction in risks for all-cause mortality (hazard ratio [HR]: 0.88, 95% CI: 0.81 to 0.95; number needed to treat [NNT]: 286 person-years), cardiovascular mortality (HR: 0.87, 95% CI: 0.79 to 0.96; NNT: 412 person-years), stroke (HR: 0.87, 95% CI: 0.76 to 0.98; NNT: 209 person-years) and the composite adverse cardiovascular outcome (MACE; HR: 0.91, 95% CI: 0.85 to 0.96; NNT: 241 person-years). The magnitude of benefit on MACE was attenuated in patients with a history of congestive heart failure (HR: 0.96, 95% CI: 0.85 to 1.08 with; HR: 0.87, 95% CI: 0.77 to 1.00 without). The risks for hospitalization for heart failure and myocardial infarction were not significantly different. The quality of the evidence was deemed as moderate to high based on GRADE approach. TSA provided firm evidence for a 10% reduction in all-cause mortality, a 15% reduction in MACE, and lack of a 15% reduction in hospitalization for heart failure, but evidence remains inconclusive for cardiovascular mortality and myocardial infarction. GLP1R agonists numerically reduced the rates for nephropathy but the risk for retinopathy was similar.

Conclusions: Meta-analysis with trial sequential analysis suggested that GLP1R agonists significantly reduced the risk for all-cause mortality and composite cardiovascular outcomes, but the reduction of cardiovascular mortality remains to be confirmed.

Keywords: Glucagon-like peptide-1 receptor agonist, Cardiovascular outcome, Microvascular outcome, Meta-analysis, Trial sequential analysis, Randomized controlled trial
**Background**

Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder associated with an increased risk for cardiovascular, microvascular and other complications [1]. The promising glucose-lowering effects as well the microvascular benefits of many anti-hyperglycemic drugs have been well documented, but the cardiovascular benefits of these drugs are uncertain [2–4]. Some hypoglycemic medications may even increase rather than reduce the risk of cardiovascular events [5, 6]. Consequently, the US Food and Drug Administration (FDA) have mandated cardiovascular safety assessments of new diabetes treatments [7, 8]. Incretin-based therapies, which include glucagon-like peptide–1 receptor (GLP1R) agonists and dipeptidyl peptidase–4 inhibitors (DDP-4i), are one of the many new anti-hyperglycemic drugs since the last decade. They have now emerged as popular treatment option for glycemic control because of their excellent performance in reducing body weight, blood pressure and postprandial lipoproteins, in addition to marked glucose lowering [9–11]. Whether these metabolic benefits might translate into cardiovascular and microvascular benefits remains an important issue. Several large-scale randomized controlled trials (RCTs) have addressed this issue but the conclusions were not consistent. In this context, we performed a meta-analysis of randomized controlled trials to investigate the effect of GLP1R agonists on cardiovascular outcomes. We also performed trial sequential analysis (TSA) to reduce type I error in meta-analysis to evaluate whether findings from meta-analyses were conclusive or not.

**Methods**

We conducted the meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Additional file 1) and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines (Additional file 2) [12].

**Data sources and searches**

We searched MEDLINE, the Cochrane Central Register of Controlled Trials, and EMBASE from their inception to 28 September 2017 without language restrictions. The following keywords were used: glucagon-like-peptide-1 receptor agonists, exenatide, liraglutide, dulaglutide, albiglutide, lixisenatide, semaglutide, tasopoglutilide, and randomized controlled trial. Reference lists of the identified reports and relevant reviews were also checked for further relevant studies.

**Study selection**

Two reviewers independently assessed the eligibility of studies. To be included, studies had to 1) be randomized controlled, cardiovascular outcome trials which made direct comparisons of glucagon-like-peptide-1 receptor agonists with placebo or active antidiabetic drugs of other classes; 2) contain at least 2000 patient-years of follow-up and 100 composite cardiovascular events to exclude small trials with unreliable hazard ratios; 3) have cardiovascular outcomes predefined and independently adjudicated; and 4) report at least one of our selected cardiovascular outcomes. Discrepancies, if any, were resolved by consensus by a third independent investigator.

**Outcome measures**

The primary endpoints were all-cause and cardiovascular death. Secondary endpoints were myocardial infarction, stroke, hospitalization for heart failure, and the major adverse cardiovascular event (MACE) defined as the composite of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke. Microvascular outcomes included nephropathy and retinopathy. We also included efficacy outcomes in the analysis.

**Data extraction and quality assessment**

Data extraction was performed by two investigators from each trial using clearly defined extraction forms. The following items were recorded: the registry number, type of treatments, number of patients, follow-up duration, patient demographic and clinical data (age, sex, duration of diabetes, baseline HbA1c levels etc.), history of cardiovascular disease (coronary artery disease, heart failure, stroke, and peripheral arterial disease), medications for diabetes and cardiovascular diseases. We also extracted the number of patients with events and the reported hazard ratio of each outcome. The same reviewers independently assessed the quality of each randomized trial according to the Cochrane Collaboration guideline [13].

**Grading of evidence**

We graded the overall methodological quality of each pooled analysis using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. The quality of evidence was judged as high, moderate, low or very low, using GRADepro version 3.6 (GRADepro GDT).

**Data synthesis and statistical analysis**

Results of meta-analyses are presented as pooled hazard ratios with their corresponding 95% confidence intervals (CIs). In cases hazard ratios were not available, we used odds ratio instead. We estimated the amount of between-study heterogeneity with the I-square statistic and the χ²-based Q test [14]. Data were pooled with the fixed-effects model (Mantel-Haenszel method) because the absence of significant heterogeneity across studies, with random-effect models (DerSimonian–Laird method) as complement [15]. The number needed to treat (NNT) was calculated from randomized trials for risk estimates where
risk difference was significant, taking into account the exposure time of treatment within each study. Publication bias was evaluated by funnel plots and Egger’s tests but these tests had limited ability to adequately assess small-study effects because all involved a small number of trials. Predefined subgroup data for MACE based on a variety of clinical variables were directly extracted from each trial and pooled subgroup analyses were conducted. We did a meta-regression analysis to estimate the effects of several covariates—age, gender, body mass index, HbA1c, duration of diabetes, and the percentage of coronary heart disease, chronic heart failure, chronic kidney disease—

| Table 1 Characteristics of included randomized controlled trials |
|---------------------------------------------------------------|
| **Trial** | ELIXA | LEADER | SUSTAIN 6 | EXCEL |
| Year      | 2015  | 2016   | 2016      | 2017   |
| No. of patients | 6068 | 9340   | 3297      | 14,752 |
| No. of countries | 49  | 32     | 20        | 35     |
| No. of study sites | NA | 310    | 230       | 687    |
| Median duration of follow-up, years | 2.1 | 3.8 | 2.1 | 3.2 |
| Median duration of exposure to treatment, years | 1.9 | 3.5 | 1.8 | 2.4 |
| **GLP1R agonist** | Lixisenatide | Liraglutide | Semaglutide | Exenatide |
| **Control** | Placebo | Placebo | Placebo | Placebo |
| Age, years | 60.3 | 64.3 | 64.6 | 56.0 |
| Male, % | 69.3 | 64.3 | 60.7 | 62.0 |
| Diabetes duration, years | 9.3 | 12.7 | 13.9 | 12.0 |
| Body mass index | 30.2 | 32.5 | 32.8 | 31.7 |
| Current smoking, % | 11.7 | NA | NA | 11.6 |
| HbA1c, % | 7.7 | 8.7 | 8.7 | 8.0 |
| Systolic blood pressure, mmHg | 129 ± 17 | 135.9 ± 17.8 | 135.6 ± 17.2 | NA |
| Diastolic blood pressure, mmHg | NA | 77.2 ± 10.3 | 77.0 ± 10.0 | NA |
| LDL cholesterol, mg/dL | 78.8 ± 35.4 | NA | 82.3 ± 45.6 | NA |
| **History of cardiovascular disease** | | | | |
| Hypertension, % | 76.4 | NA | 92.8 | NA |
| Coronary artery disease, % | 100 | 81.4 | 60.4 | 52.9 |
| Heart failure, % | 22.4 | 17.9 | 24.3 | 16.6 |
| Stroke, % | 5.5 | NA | 12.4 | 17.3 |
| Peripheral arterial disease, % | 7.7 | NA | NA | 18.9 |
| Chronic kidney disease, % | 23.2 | 24.7 | 28.5 | 21.7 |
| **Diabetes medications** | | | | |
| Insulin, % | 39.1 | 44.6 | 58.0 | 46.4 |
| Metformin, % | 66.3 | 76.4 | 73.2 | 76.8 |
| Sulfonylureas, % | 33.2 | 50.5 | 42.8 | 36.6 |
| Thiazolidinediones, % | 1.6 | 6.2 | 2.3 | 3.9 |
| DPP-4 inhibitor, % | NA | <0.1 | 0.2 | 15.0 |
| **Cardiovascular Medications** | | | | |
| ACEI or ARB, % | 85.0 | 82.8 | 83.5 | 80.0 |
| Statin, % | 92.7 | 72.1 | 72.8 | 73.5 |
| Anti-thrombotic, % | 97.5 | 74.3 | 76.3 | 73.6 |
| Beta-blocker, % | 84.5 | 55.4 | 57.4 | 55.8 |
| Aldosterone antagonists, % | NA | 5.4 | 5.9 | 6.2 |
| NCT No. | NCT01147250 | NCT01179048 | NCT01720446 | NCT02098395 |

ACEI: angiotensin-converting-enzyme inhibitor, ARB: angiotensin receptor antagonist, GLP1R: glucagon-like peptide 1–receptor agonist, LDL: low-density lipoprotein cholesterol, NA: not available
might have on endpoints with significant association. For the effect estimate, a 2-tailed \( p \) value less than 0.05 was considered statistically significant. Analyses were done by using the Stata software, version 12.0 (STATA Corporation, College Station, TX, USA).

TSA could reduce type I error because it combines estimation of required information size with adjusted threshold for statistical significance [16–18]. The required information size was calculated based on a relative risk reduction of 10% in all-cause and cardiovascular mortality and a relative risk reduction of 15% in other outcomes. An overall 5% risk of type I error and a statistical test power of 80% were employed.

Results
Study selection and characteristics
Of 1980 citations initially identified, 71 were retrieved for full-text evaluation and 4 trials (ELIXA, LEADER, SUSTAIN 6, and EXSCEL) met inclusion criteria (Additional file 3: Figure S1) [19–22]. A total of 33,457 patients receiving GLP1R agonists \((n = 16,706)\) or placebo \((n = 16,751)\) were included in the analysis. All 4 trials were large, prospective, multicenter, double-blind, randomized placebo-controlled trials with independent cardiovascular endpoint adjudication and adequate follow-up time (range 6924–47,206 patient-years of follow-up). All trials were performed across multiple countries. The mean age enrolled in all the included trials ranged from 56 to 65 years, the mean duration of diabetes from 9.3 to 13.9 years, the mean HbA1c level from 7.7 to 8.7%, and the mean body mass index ranged from 30.2 to 32.8. Overall, 64% patients were male, 70% had a history of coronary heart disease, 18% had heart failure and 23.5% had chronic kidney disease. 46% patients had concomitant insulin use, 74.4% had metformin, 40% had sulfonylureas; new anti-diabetic drugs such as DDP4i and sodium-glucose cotransporter-2 inhibitors were used in very limited number of patients. Cardiovascular medications and other detailed baseline characteristics of each trial are presented in Table 1. Primary and secondary endpoints, inclusion and exclusion criteria of included randomized controlled trials were presented in (Additional file 3: Table S1).

The method of random sequence generation was reported in all trials. All trials had blinding of personnel and participants. In 2 trials, blinded outcome adjudication was not performed, so they were judged as being of unclear risk of bias. The risk for detection bias, attrition bias, reporting bias and other bias were generally low. All 4 trials were deemed as good quality, with detailed quality assessment summarized in Additional file 3: Table S2).

Total and cardiovascular mortality
There were 1161 deaths among 16,706 patients randomly assigned to receive GLP1R agonists and 1314 deaths among 16,751 patients assigned to placebo. Pooled analysis showed a statistically significant reduction in all-cause mortality with GLP1R agonists compared with placebo (HR: 0.88, 95% CI: 0.81 to 0.95, \( p = 0.001 \); Fig. 1); the NNT was 286 person-years’ exposure to treatment. No evidence of significant heterogeneity was found (\( I^2 = 0 \)). TSA showed that although the pooled sample size did not exceed the estimated required information size, the cumulative Z-curve crossed the conventional boundary and also the trial sequential monitoring.
boundary (Fig. 2), providing firm evidence for a 10% reduction in total mortality with GLP1R agonists when compared with placebo.

Of 16,706 patients assigned to GLP1R agonists, 759 experienced cardiovascular death, as did 865 of 16,751 patients with placebo. Overall, there was a statistically significant reduction in cardiovascular mortality with use of GLP1R agonists (HR: 0.87, 95% CI: 0.79 to 0.96, \( P = 0.005 \)) (Fig. 1); the number needed to treat was 412 person-years’ exposure to treatment. Similarly, no heterogeneity was detected \( (I^2 = 0) \). In TSA, the Z-curve crossed the conventional boundary but did not cross the monitoring boundary, indicating a 10% reduction in cardiovascular mortality with GLP1R agonists was inconclusive and that additional evidence is needed (Fig. 3). The risk for non-cardiovascular death was not significantly different (HR: 0.90, 95% CI: 0.78 to 1.03, \( P = 0.11 \)).

**Myocardial infarction and stroke**

Meta-analysis did not show statistically significant difference in incidence of myocardial infarction between patients with GLP1R agonists and those with placebo (HR: 0.94, 95% CI: 0.86 to 1.02, \( P = 0.143 \); Fig. 4). GLP1R agonists were associated with a statistically significant reduction in rates of stroke (HR: 0.87, 95% CI: 0.76 to 0.98, \( P = 0.023 \); Fig. 4); the number needed to treat was
209 person-years’ exposure to treatment. We did not find significant heterogeneity in both comparisons ($I^2 = 24.4\%$ and 28.8\% respectively). TSA suggested that a 15\% reduction in myocardial infarction and stroke was inconclusive and future trials are needed (Additional file 3: Figures S2 and S3).

Hospitalization for heart failure

There was no significant difference in rate of hospitalization for heart failure between the use of GLP1R agonists and placebo (HR: 0.93, 95\% CI: 0.83 to 1.04, $P = 0.203$) (Fig. 4). We did not find evidence of heterogeneity across these trials ($I^2 = 0$). In TSA, the cumulative Z-curve crossed the futility area, suggesting firm evidence for lack of a 15\% relative risk reduction in risk for hospitalization for heart failure (Additional file 3: Figure S4).

Major adverse cardiovascular event

Treatment with GLP1R agonists resulted in a statistically significant reduction in MACE compared with placebo; rates were 11.7\% (1961 of 16,706 patients) and 12.8\% (2144 of 16,751 patients) respectively (HR: 0.91, 95\% CI: 0.85 to 0.96, $P = 0.002$) (Fig. 4). Considerable heterogeneity was detected ($I^2 = 50.1\%$); the number needed to treat was 241 person-years’ exposure to treatment. TSA showed that the pooled sample size exceeded the estimated required information size and the cumulative Z-curve.
crossed both the conventional boundary and the trial sequential monitoring boundary, indicating that there is firm evidence for a 15% reduction in risk for MACE with GLP1R agonists when compared with placebo (Fig. 5).

Largely consistent results on MACE were found across a number of subgroup analyses. The magnitude of the benefit of GLP1R agonists on MACE was attenuated in patients with a younger age, with a body mass index less than 30, with a history of congestive heart failure (Additional file 3: Figure S5), but the tests for interaction were not significant (Table 2).

Microvascular outcomes

The rates for nephropathy was numerically lower in patients with GLP1R agonists than placebo (648/13680 versus 757/13709, OR: 0.80, 95% CI: 0.60 to 1.06, P = 0.121) (Fig. 6). There was no significant difference in risk for retinopathy (370/13680 versus 359/13709, OR: 1.15, 95% CI: 0.83 to 1.60, P = 0.394) between the use of GLP1R agonists and placebo (Fig. 6). Significant heterogeneity was detected across trials in both analyses (I² = 83.7% and 73.5% respectively).

Grading of evidence

Based on GRADE summaries (Table 3), we deemed the quality of the evidence to be high for total and cardiovascular mortality and stroke, and moderate for other outcomes. Reasons for rating down were provided in Table 3.

Efficacy outcomes

GLP1R agonists significantly reduced HbA1c level compared with placebo, with a weighted mean difference of −0.57% (95% CI: −0.74 to −0.40) (Fig. 7). GLP1R agonists also significantly reduced body weight (WMD: −2.25 kg; 95% CI: −3.09 to −1.41) and systolic blood pressure (WMD: −1.33 mmHg; 95% CI: −1.80 to −0.86), and increased heart rate (WMD: 2.07 beats per minute; 95% CI: 0.87 to 3.27).
In this meta-analysis of 33,457 patients and 4105 cardiovascular events from 4 large double-blind, randomized placebo-controlled cardiovascular outcome trials, we showed that 1) GLP1R agonists were associated with a statistically significant reduction in risks for all-cause (high-quality evidence), cardiovascular mortality (high-quality evidence), stroke (high-quality evidence) and the composite outcome of cardiovascular mortality, nonfatal myocardial infarction or nonfatal stroke (moderate-quality evidence); 2) the risks for hospitalization for heart failure and myocardial infarction were not significantly different (moderate-quality evidence); 3) TSA provided firm evidence for a 10% reduction in all-cause mortality, a 15% reduction in MACE, and lack of a 15% reduction in hospitalization for heart failure with GLP1R agonists compared with placebo, but evidence remains inconclusive for cardiovascular mortality and myocardial infarction; 4) the magnitude of the benefit of GLP1R agonists on MACE was more remarkable in patients without a history of congestive heart failure but attenuated in patients with; 5) GLP1R agonists numerically reduced the rates for nephropathy but the risk for retinopathy was similar; 6) GLP1R agonists showed sustained reduction in HbA1c level and a number of other metabolic risk factors.

Several previous meta-analyses have evaluated the cardiovascular effect of GLP1R [23–25]. Two analyses reported
no substantial difference in risk for total mortality or the major composite outcomes between GLP1R agonists and control treatments [23, 24]. These analyses were limited to RCTs primarily to evaluate the glucose-lowering efficacy of GLP1R agonists, all with the number of cardiovascular events as few as tens and the number of participants from tens to hundreds. Cardiovascular outcomes in these trials were based on clinician-reported adverse events rather than predefined and independently adjudicated. Another meta-analysis [25] included 3 of the cardiovascular outcome trials. They found that GLP1R agonists were associated with a lower mortality (odds ratio: 0.89; 95% CI: 0.80 to 0.99), but the risk for MACE was not significantly different (odds ratio: 0.88; 95% CI: 0.74 to 1.04). The important EXSCEL trial [22]—the largest trial among the 4 cardiovascular outcome trials was not included in their analysis. Incorporating data from EXSCEL trial to our analysis substantially improved the power of meta-analysis to detect potential difference of rare outcomes (adding another 14,752 patients and 1091 cardiovascular events). Compared with the analysis by Liu and colleagues which only detected total mortality benefit of GLP1R agonists, we extended the benefits to cardiovascular mortality, stroke and the composite MACE. We provided the funnel plots showing the trajectory of the overall point estimates and their corresponding precision evolved as each trial entered the meta-analysis. It can be seen that the benefits on MACE became significant until the EXSCEL trial was included. Another difference was that we employed HR rather than odds ratio in pooled analyses. We chose HR because it

### Table 2 Subgroup analyses for MACE

| Subgroups                  | HR (95% CI)       | P value | P value for interaction |
|----------------------------|-------------------|---------|-------------------------|
| Age                        |                   |         |                         |
| < 60–65 years              | 0.92 (0.77, 1.10) | 0.38    | 0.58                    |
| ≥ 60–65 years              | 0.85 (0.79, 0.93) | 0.001   |                         |
| Gender                     |                   |         |                         |
| Male                       | 0.91 (0.85, 0.98) | 0.02    | 0.53                    |
| Female                     | 0.87 (0.78, 0.98) | 0.02    |                         |
| Race                       |                   |         |                         |
| White                      | 0.94 (0.88, 1.01) | 0.09    | 0.12                    |
| Black                      | 0.77 (0.59, 1.00) | 0.05    |                         |
| Asian                      | 0.78 (0.62, 0.97) | 0.03    |                         |
| Body mass index            |                   |         |                         |
| < 30 kg/m²                 | 0.93 (0.83, 1.05) | 0.22    | 0.69                    |
| ≥ 30 kg/m²                 | 0.88 (0.81, 0.96) | 0.008   |                         |
| Glycated hemoglobin level  |                   |         |                         |
| < 8.0–8.5%                 | 0.91 (0.83, 1.00) | 0.04    | 0.73                    |
| ≥ 8.0–8.5%                 | 0.89 (0.82, 0.97) | 0.01    |                         |
| Insulin therapy            |                   |         |                         |
| Yes                        | 0.88 (0.81, 0.97) | 0.01    | 0.98                    |
| No                         | 0.88 (0.80, 0.98) | 0.01    |                         |
| Duration of diabetes       |                   |         |                         |
| < 10–15 years              | 0.91 (0.81, 1.02) | 0.09    | 0.74                    |
| ≥ 10–15 years              | 0.89 (0.82, 0.96) | < 0.01  |                         |
| History of congestive heart failure |       |         |                         |
| Yes                        | 0.96 (0.85, 1.08) | 0.47    | 0.27                    |
| No                         | 0.87 (0.77, 1.00) | 0.05    |                         |
| Estimated GFR              |                   |         |                         |
| ≥ 60 mL/min/1.73m²         | 0.91 (0.79, 1.05) | 0.19    | 0.82                    |
| < 60 mL/min/1.73m²         | 0.89 (0.72, 1.09) | 0.25    |                         |
| ≥ 30 mL/min/1.73m²         | 0.88 (0.82, 0.95) | < 0.001 | 0.81                    |
| < 30 mL/min/1.73m²         | 0.87 (0.55, 1.39) | 0.57    |                         |

CI confidence interval, GFR glomerular filtration rate, HR hazard ratio, MACE major adverse cardiovascular event
allows harmonization of the time-period variability across the trials. Although the direction of results might not be changed using different effect of estimates, the magnitudes of benefit were different. Finally, we determined whether findings from meta-analyses were conclusive by performing TSA and assessed the quality of evidence using the GRADE approach. These comprehensive analyses provide convincing evidence that GLP1R agonists reduce total mortality and MACE.

The US Food and Drug Administration (FDA) requires that all new anti-diabetic drugs must demonstrate good cardiovascular safety with an upper boundary of risk < 1.3. [26] This statement was first raised because a strong and consistent relationship with increased risk of heart failure was reported to be associated with rosiglitazone [5, 6]. Cardiovascular concern has also latter been raised with DDP-4i [27] particularly for saxagliptin [28] also with regard to the risk of admission to hospital for heart failure. Heart failure, one important diabetes complication with high frequency, morbidity and mortality, has previously been relegated to an inferior position compared with microvascular and macrovascular complications in diabetes [4]. Due to this emerging concern, the FDA has now called to have heart failure systematically assessed in cardiovascular outcome trials of all new glucose-lowering drugs [29]. Our analysis, based on >

Table 3  GRADE assessment of confidence in estimates of effect in randomized trials

| Outcome                  | No. of participants (trials) | Risk of bias          | Consistency | Directness | Precision | Publication bias | Quality |
|--------------------------|------------------------------|-----------------------|-------------|------------|-----------|-----------------|---------|
| MACE                     | 33,457 (4)                   | No serious limitations | No serious limitations | No serious limitations | No serious limitations | No serious limitations | Moderate |
| All-cause death          | 33,457 (4)                   | No serious limitations | No serious limitations | No serious limitations | No serious limitations | No serious limitations | High     |
| Cardiovascular death     | 33,457 (4)                   | No serious limitations | No serious limitations | No serious limitations | No serious limitations | No serious limitations | High     |
| Myocardial infarction    | 33,457 (4)                   | No serious limitations | No serious limitations | No serious limitations | No serious limitations | No serious limitations | Moderate |
| Stroke                   | 33,457 (4)                   | No serious limitations | No serious limitations | No serious limitations | No serious limitations | No serious limitations | High     |
| Hospitalization for heart failure | 33,457 (4) | No serious limitations | No serious limitations | No serious limitations | No serious limitations | No serious limitations | Moderate |

GRADE Grading of Recommendations Assessment, Development and Evaluation

aModerate to substantial heterogeneity: I² = 50.1%
bI² = 24.4 and 28.8% respectively. Did not downgrade for mild heterogeneity
c95% confidence interval (CI) include important harm and benefit
dDid not downgrade even though Egger's test detected a possible publication bias. We did not downgrade because all trials included were large-scale randomized trials and these tests had limited ability to adequately assess small-study effects due to a small number of trials

Fig. 6 Effects of GLP1R agonists on nephropathy and retinopathy. CI, confidence interval; GLP1R, glucagon-like peptide–1 receptor; OR, odds ratio
33,000 patients and 4000 cardiovascular events, provided robust reassurance about the cardiovascular safety of GLP1R agonists, showing no increase in risks for hospitalization for heart failure and myocardial infarction. The upper boundary of risk of each individual and composite outcome was far less than 1.3 in our analysis. Our exploratory finding that the magnitude of the benefit of GLP1R agonists on MACE was more remarkable in patients without a history of congestive heart failure but attenuated in patients with remain to be confirmed in future studies. If confirmed, it would have great impact in the selection of patients for GLP1R agonist use.

Moreover, we found that GLP1R agonists instead reduced the risk for a number of cardiovascular outcomes. In our analysis, a 10% risk reduction in all-cause mortality and a 15% reduction in MACE were evident, although a 10% reduction in cardiovascular mortality still remains inconclusive. The relative risk reduction may seem relatively small, however, it should be duly noted that these benefits were observed in a population with the majority, if not all, patients had established cardiovascular disease (CVD) or at high cardiovascular risk in whom other cardiovascular risk factors were well treated. A large portion of patients were taking concomitant cardiovascular protection medications such as renin–angiotensin–aldosterone system inhibitors, β-blockers, statins or ezetimibe, and acetylsalicylic acid etc. Therefore, the cardiovascular protective effect of GLP1R agonists appears to be additive to that of evidence-based cardiovascular pharmacotherapies [30, 31]. Another important finding of our study was that total mortality was significantly reduced with GLP1R agonists. This finding was considered critically important because the common use of evidence-based cardiovascular pharmacotherapies substantially lower the incidence of mortality, which makes potential difference difficult to detect. For instance, more intensive low-density lipoprotein (LDL)
cholerolowering therapy with PCSK9 antibodies or ezetimibe did not show benefit in reducing cardiovascular and total mortality, although a reduced composite outcomes was observed [32–34].

Previous guidelines in cardiology did not make a recommendation on the selection of anti-hyperglycemic drugs in diabetes patients with established CVD or at high cardiovascular risk [30, 31]. The recently published cardiovascular outcomes trials of new antidiabetic therapies have provided additional data on cardiovascular outcomes in patients with type 2 diabetes with cardiovascular disease or at high risk for CVD [19–22, 28, 35–38]. The 2018 Standards of Medical Care in Diabetes recommends that in this population, anti-hyperglycemic therapy should begin with metformin and subsequently incorporate an agent proven to reduce major adverse cardiovascular events and cardiovascular mortality (currently empagliflozin and liraglutide) [39]. Our analyses support the recommendation that anti-hyperglycemic drugs should be chosen with preference in diabetes patients with established CVD or at high cardiovascular risk, with GLP1R agonists and also sodium–glucose cotransporter 2 inhibitors [35] as priority, after considering drug-specific and patient factors.

The mechanisms of cardiovascular protection associated with GLP1R agonists are considered multidimensional, which was discussed elsewhere [40]. It may be associated with reduction of body weight, blood pressure, the lipid profile and lowering the risk for hypoglycemia, and amelioration of insulin resistance and inflammation, etc. Although our findings were obtained in the context of no obvious heterogeneity among trials, whether the cardiovascular benefits of GLP1R agonists represent a class effect remains to be definitively established. Other large-scale randomized controlled cardiovascular outcome trials are ongoing, such as the ITCA 650 trial (NCT01455896) with 4000 patients and the REWIND (Researching Cardiovascular Events With a Weekly InNcretin in Diabetes, NCT01394952) with 9622 patients (Additional file 3: Table S3). Of note, overexpression of mTOR stimulated GLP-1 production, indicating a link role of mTOR between energy supply and the production of GLP-1 [41]. Indeed, inhibition of mTOR with rapamycin attenuated inflammation, inhibited progression, and enhanced stability of atherosclerotic plaques in animal models [42]. The potential effect of the inhibition of the mTOR pathway in the treatment of cardiovascular diseases warrants further investigation.

**Limitations**

We acknowledge several limitations. First, the results were analyzed on trial level data but not on patient level data; individual patient-level data could improve the accuracy of the findings. Second, our finding that the magnitude of the benefit of GLP1R agonists on MACE was more remarkable in patients without a history of congestive heart failure but attenuated in patients with an only be considered exploratory and remain to be confirmed in future studies. Third, publication bias tests had limited ability to adequately assess small-study effects because all involved a small number of trials. Fourth, the conclusions were based on diabetes patients with established or high risk for CVD and could be generalized to patients with low cardiovascular risk.

**Conclusions**

Moderate-to-high quality of evidence suggested that GLP1R agonists did not increase the risk for any of, but instead reduced the risk for a number of cardiovascular outcomes. A 10% reduction in all-cause mortality and a 15% reduction in the composite outcome of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke were evident. In diabetes patients with established CVD or at high cardiovascular risk, GLP1R agonists could be a preferred anti-hyperglycemic agent after considering drug-specific and patient factors. Future studies are needed to confirm the long-term cardiovascular benefits of GLP1R agonists.

**Additional files**

Additional file 1: PRISMA checklist. (DOCX 22 kb)
Additional file 2: MOOSE checklist. (DOC 71 kb)
Additional file 3: Figure S1. Flow diagram of study selection; Table S1. Primary and secondary endpoints, inclusion and exclusion criteria of included randomized controlled trials; Table S2. Risk of bias of included randomized controlled trials; Figure S2. Trial sequential analysis for myocardial infarction in patients receiving glucagon-like peptide-1 receptor agonists versus placebo; Figure S3. Trial sequential analysis for stroke in patients receiving glucagon-like peptide-1 receptor agonists versus placebo; Figure S4. Trial sequential analysis for hospitalization for heart failure in patients receiving glucagon-like peptide-1 receptor agonists versus placebo; Figure S5. Analysis of MACE based on patients with or without a history of congestive heart failure; Table S3. Characteristics of large ongoing randomized controlled trials evaluating cardiovascular efficacy of GLP-1 receptor agonist. (DOCX 1010 kb)

**Abbreviations**

CIs: Confidence intervals; CVD: Cardiovascular disease; DDP-4i: Dipeptidyl peptidase-4 inhibitors; FDA: Food and Drug Administration; GLP1R: Glucagon-like peptide-1 receptor; GRADE: Grading of Recommendations, Assessment, Development and Evaluation; HR: Hazard ratio; LDL: Low-density lipoprotein; MACE: Major adverse cardiovascular event; NNT: Number needed to treat; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCTs: Randomized controlled trials; T2DM: Type 2 diabetes mellitus; TSA: Trial sequential analysis

**Funding**

This work was supported by National Natural Science Foundation of China (81800752), Natural Science Foundation of Jiangsu Province (BK20170125), Jiangsu Provincial Key Medical Discipline (ZDXK201601D), and the Key Research and Development Program of Jiangsu Province of China (BE2015604 and BE2016606). The funders had no role in the study design, data collection and analysis, writing of the report, and decision to submit the article for publication.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article and its supplementary materials.
Authors’ contributions
XZ conceived the study, selected studies and extracted the data, analyzed and interpreted the data, and wrote the first draft of the manuscript. FS selected studies and extracted the data, analyzed and interpreted the data, and wrote the first draft of the manuscript. LZ and YZ contributed to the study protocol and analyzed and interpreted the data. DZ and YB conceived the study, interpreted the data, and wrote the first draft of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1. Department of Endocrinology, Affiliated Drum Tower Hospital, Nanjing University School of Medicine, 321 Zhongshan Road, Nanjing, Jiangsu Province 210008, China. 2. Department of Endocrinology, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, 321 Zhongshan Road, Nanjing, Jiangsu Province 210008, China.

Received: 24 May 2018 Accepted: 28 August 2018

Published online: 17 September 2018

References
1. Di Angelantonio E, Kaptoge S, Wormser D, Willett P, Butterworth AS, Bnsal N, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314:52–60.
2. Gerstein HC, Miller ME, Genueth S, Ismail-Beigi F, Buse JB, Goff DJ, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818–28.
3. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.
4. Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hypoglycaemic drug therapy. Lancet. 2015;385:2107–17.
5. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71.
6. Singh S, LoKe YK, Furberg CD. Thiazolidinediones and heart failure: a teleological analysis. Diabetes Care. 2007;30:2148–53.
7. Holman RR, Sourni H, Calif RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383:2003–17.
8. Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med. 2008;359:1092–5.
9. Waldrop G, Zhong J, Peters M, Rajagopalan S. Incretin-based therapy for diabetes: what a cardiologist needs to know. J Am Coll Cardiol. 2016;67:1488–96.
10. Eliasson B, Moller-Goede D, Eeg-Olofsson K, Wilson C, Cederholm J, Fleck P, Diamant M, Taskinen MR, Smith U. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia. 2012;55:915–25.
11. Eng C, Kramer CK, Zimmab B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384:2228–34.
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9. W64
13. Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. http://handbook-5.1.cochrane.org/. Accessed 28 Sept 2017.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
15. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.
16. Winterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61:64–75.
17. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trials. 1997;18:580–93.
18. Brok J, Thorlund K, Winterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive—trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol. 2009;38:287–98.
19. Marzo SP, Daniels GH, Brown-Brandt K, Kristensen P, Mann JF, Nauck MA, et al. Liixaglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.
20. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al. Liixaglutide and cardiovascular outcomes in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–57.
21. Ha SJ, Sp Iain SC, Consoli A, Blaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;19(1834–44.
22. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygyna Y, Busse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–39.
23. Ding S, Du YP, Lin N, Su YY, Yang F, Kong LC, Ge H, Pu J, He B. Effect of glucagon-like peptide-1 on major cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Int J Cardiol. 2016;222:957–62.
24. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:38–47.
25. Liu J; Li L, Deng K, Xu C, Busse JW, Vandyk PO, Li S, Guyatt GH, Sun X. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ; 2017;357:j2499.
26. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf. Accessed 28 Sept 2017.
27. Li L, Li S, Deng K, Liu J, Vandyk PO, Zhao P, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ; 2016;1610.
28. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–26.
29. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2:843–51.
30. O’Gara PT, Kushner FG, Ascheim DD, Casey D, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2013;61:e78–140.
31. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949–3003.
32. Ridker PM, Revkin J, Amarenco P, Brunelli R, Carro M, Civeira F, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;316:1527–39.
33. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;318:713–22.
34. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.
35. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;372:2117–28.
36. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.
37. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35.
38. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–42.
39. Standards of Medical Care in Diabetes—2018. Diabetes Care. 2018; Supplement 1:S1–155.
40. Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136:849–70.
41. Xu G, Li Z, Ding L, Tang H, Guo S, Liang H, Wang H, Zhang W. Intestinal mTOR regulates GLP-1 production in mouse L cells. Diabetologia. 2015;58:1887–97.
42. Tarantino G, Capone D. Inhibition of the mTOR pathway: a possible protective role in coronary artery disease. Ann Med. 2013;45:348–56.